Article Text

Download PDFPDF
ESRA19-0150 Clinical application of an SCS device capable of patient-selective use of multiple available neurostimulative treatment options for chronic pain: real-world outcomes from europe
  1. P De Negri1,
  2. MA Canos-Verdecho2,
  3. L Chen3 and
  4. R Jain3
  1. 1Hospital San Giuliano, Pain Center, Giugliano in Campania, Italy
  2. 2University and Polytechnic Hospital La Fe, Pain Unit, Valencia, Spain
  3. 3Boston Scientific Neuromodulation, Clinical, Valencia, USA


Background and aims Despite notable advances, there are no clear-cut, objective tools to definitively identify which of the several available spinal cord stimulation (SCS)-based approaches are likely to induce robust pain relief within any given patient. Given this and the inherent subjective manifestation of pain, therapeutic devices that are equipped to provide multiple treatment options, thereby enabling patient-selective use of different modalities of neurostimulation, are expected to become increasingly essential when employing SCS for chronic pain. In this report, we describe our own real-world clinical experience using such an SCS system within a highly diverse cohort of implanted chronic pain patients.

Methods This is an observational case-series conducted at sites in Europe as part of an ongoing retrospective chart review evaluation of SCS outcomes for chronic pain ( identifier: NCT01550575). Patients were implanted with an SCS system (Precision Spectra/Montage, Boston Scientific) capable of multiple waveforms (standard tonic stimulation, 1 kHz sub/supra-perception, burst, other). Assessments collected include (but not limited to) baseline characteristics (demographics, medical history, pain diagnosis), procedural information (lead configuration, programming parameters), and pre- and post-implant pain and patient treatment preference

Results To date, data analysis is currently ongoing. Results from the initial cohort of included patients will be presented.

Conclusions SCS devices that provide patients with greater control and customization of therapy offer potential for better management of chronic pain over time including possible mitigation of neural tolerance, reduced post-implantation follow-up evaluation, and opportunity to use different neurostimulative options without need to replace the implantable pulse generator (IPG).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.